IBDEI2T8 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,44821,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 10-19% Body Surface
 ;;^UTILITY(U,$J,358.3,44821,1,4,0)
 ;;=4^L49.1
 ;;^UTILITY(U,$J,358.3,44821,2)
 ;;=^5009191
 ;;^UTILITY(U,$J,358.3,44822,0)
 ;;=L49.2^^170^2237^18
 ;;^UTILITY(U,$J,358.3,44822,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44822,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 20-29% Body Surface
 ;;^UTILITY(U,$J,358.3,44822,1,4,0)
 ;;=4^L49.2
 ;;^UTILITY(U,$J,358.3,44822,2)
 ;;=^5009192
 ;;^UTILITY(U,$J,358.3,44823,0)
 ;;=L49.3^^170^2237^19
 ;;^UTILITY(U,$J,358.3,44823,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44823,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 30-39% Body Surface
 ;;^UTILITY(U,$J,358.3,44823,1,4,0)
 ;;=4^L49.3
 ;;^UTILITY(U,$J,358.3,44823,2)
 ;;=^5009193
 ;;^UTILITY(U,$J,358.3,44824,0)
 ;;=L49.4^^170^2237^20
 ;;^UTILITY(U,$J,358.3,44824,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44824,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 40-49% Body Surface
 ;;^UTILITY(U,$J,358.3,44824,1,4,0)
 ;;=4^L49.4
 ;;^UTILITY(U,$J,358.3,44824,2)
 ;;=^5009194
 ;;^UTILITY(U,$J,358.3,44825,0)
 ;;=L49.5^^170^2237^21
 ;;^UTILITY(U,$J,358.3,44825,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44825,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 50-59% Body Surface
 ;;^UTILITY(U,$J,358.3,44825,1,4,0)
 ;;=4^L49.5
 ;;^UTILITY(U,$J,358.3,44825,2)
 ;;=^5009195
 ;;^UTILITY(U,$J,358.3,44826,0)
 ;;=L49.6^^170^2237^22
 ;;^UTILITY(U,$J,358.3,44826,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44826,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 60-69% Body Surface
 ;;^UTILITY(U,$J,358.3,44826,1,4,0)
 ;;=4^L49.6
 ;;^UTILITY(U,$J,358.3,44826,2)
 ;;=^5009196
 ;;^UTILITY(U,$J,358.3,44827,0)
 ;;=L49.7^^170^2237^23
 ;;^UTILITY(U,$J,358.3,44827,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44827,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 70-79% Body Surface
 ;;^UTILITY(U,$J,358.3,44827,1,4,0)
 ;;=4^L49.7
 ;;^UTILITY(U,$J,358.3,44827,2)
 ;;=^5009197
 ;;^UTILITY(U,$J,358.3,44828,0)
 ;;=L49.8^^170^2237^24
 ;;^UTILITY(U,$J,358.3,44828,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44828,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 80-89% Body Surface
 ;;^UTILITY(U,$J,358.3,44828,1,4,0)
 ;;=4^L49.8
 ;;^UTILITY(U,$J,358.3,44828,2)
 ;;=^5009198
 ;;^UTILITY(U,$J,358.3,44829,0)
 ;;=L49.9^^170^2237^27
 ;;^UTILITY(U,$J,358.3,44829,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44829,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ > 89% Body Surface
 ;;^UTILITY(U,$J,358.3,44829,1,4,0)
 ;;=4^L49.9
 ;;^UTILITY(U,$J,358.3,44829,2)
 ;;=^5009199
 ;;^UTILITY(U,$J,358.3,44830,0)
 ;;=Z65.5^^170^2237^28
 ;;^UTILITY(U,$J,358.3,44830,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44830,1,3,0)
 ;;=3^Exposure to Disaster/War/Hostilities
 ;;^UTILITY(U,$J,358.3,44830,1,4,0)
 ;;=4^Z65.5
 ;;^UTILITY(U,$J,358.3,44830,2)
 ;;=^5063184
 ;;^UTILITY(U,$J,358.3,44831,0)
 ;;=Z77.22^^170^2237^29
 ;;^UTILITY(U,$J,358.3,44831,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44831,1,3,0)
 ;;=3^Exposure to/Contact w/ Environmental Tobacco Smoke
 ;;^UTILITY(U,$J,358.3,44831,1,4,0)
 ;;=4^Z77.22
 ;;^UTILITY(U,$J,358.3,44831,2)
 ;;=^5063324
 ;;^UTILITY(U,$J,358.3,44832,0)
 ;;=L30.9^^170^2237^5
 ;;^UTILITY(U,$J,358.3,44832,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44832,1,3,0)
 ;;=3^Eczema,Unspec
 ;;^UTILITY(U,$J,358.3,44832,1,4,0)
 ;;=4^L30.9
 ;;^UTILITY(U,$J,358.3,44832,2)
 ;;=^5009159
